Rory Collins

Last updated

Sir Rory Collins
Born
Rory Edwards Collins

(1955-01-03) 3 January 1955 (age 69) [1]
Hong Kong [1]
Alma mater
Known for UK Biobank [2] [3] [4]
Awards
Scientific career
Fields
Institutions University of Oxford
Website www.ndph.ox.ac.uk/team/rory-collins

Sir Rory Edwards Collins FMedSci FRS [5] (born 3 January 1955) is a British physician who is Professor of Medicine and Epidemiology at the Clinical Trial Service Unit within the University of Oxford, the head of the Nuffield Department of Population Health and a Fellow of Green Templeton College, Oxford. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies ("meta-analyses"). [6] [7] [8] Since September 2005, he has been the Principal Investigator and Chief Executive of the UK Biobank, [2] [3] [4] a prospective study of 500,000 British people aged 40–69 at recruitment.

Contents

Education

Collins was educated at Dulwich College [1] and studied Medicine at St Thomas's Hospital Medical School, part of the University of London (1974–1980), and Statistics at George Washington University from 1976 to 1977 and the University of Oxford from 1982 to 1983.[ citation needed ]

Career and research

Since 1985, Collins has been co-director with Sir Richard Peto of the University of Oxford's Clinical Trial Services and Epidemiological Studies units. In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation. Since September 2005, he has also been acting as the Principal Investigator and Chief Executive of the UK Biobank, [2] [3] [4] a prospective study of 500,000 British people, aged 40–69 at recruitment.

Collins' work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer. [9]

He has created and led large studies that transformed statins from esoteric drugs for familial hypercholesterolaemia into widely-used generics that prevent millions of heart attacks and ischaemic strokes annually. His large placebo-controlled trials and worldwide Cholesterol Treatment Trialists' meta-analyses confirmed that statins reduce the risk of heart attack, discovered that they reduce the risk of stroke, and demonstrated their safety and efficacy in many different types of patient. [5] His research has been funded by the Medical Research Council (MRC). [10]

Awards and honours

Collins was knighted in the 2011 New Year Honours for services to science. [11] He was elected as a Fellow of the Academy of Medical Sciences in 2004 and a Fellow of the Royal Society (FRS) in 2015. [5] Collins was included in Time's 2024 list of 100 most influential people in health. [12]

Related Research Articles

<span class="mw-page-title-main">Statin</span> Class of drugs to lower cholesterol

Statins are a class of medications that reduce illness and mortality in people who are at high risk of cardiovascular disease.

<span class="mw-page-title-main">Scandinavian Simvastatin Survival Study</span>

The Scandinavian Simvastatin Survival Study, was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina. The study was sponsored by the pharmaceutical company Merck and enrolled 4,444 people from 94 centres in Scandinavia.

<span class="mw-page-title-main">Cardiovascular disease</span> Class of diseases that involve the heart or blood vessels

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery diseases, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

<span class="mw-page-title-main">Hypercholesterolemia</span> High levels of cholesterol in the blood

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, hyperlipoproteinemia, and dyslipidemia.

<span class="mw-page-title-main">Heart Protection Study</span>

The Heart Protection Study was a randomized controlled trial run by the Clinical Trial Service Unit, and funded by the Medical Research Council (MRC) and the British Heart Foundation (BHF) in the United Kingdom. It studied the use of the cholesterol lowering drug, simvastatin 40 mg and vitamin supplementation in people who were at risk of cardiovascular disease. It was led by Jane Armitage, an epidemiologist at the Clinical Trial Service Unit.

<span class="mw-page-title-main">Stroke</span> Death of a region of brain cells due to poor blood flow

Stroke is a medical condition in which poor blood flow to the brain causes cell death. There are two main types of stroke:

<span class="mw-page-title-main">Atorvastatin</span> Cholesterol-lowering medication

Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention of cardiovascular disease, statins are a first-line treatment. It is taken by mouth.

<span class="mw-page-title-main">Simvastatin</span> Lipid-lowering medication

Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. It is also used to decrease the risk of heart problems in those at high risk. It is taken by mouth.

<span class="mw-page-title-main">Indapamide</span> Thiazide-like diuretic drug

Indapamide is a thiazide-like diuretic drug used in the treatment of hypertension, as well as decompensated heart failure. Combination preparations with perindopril are available. The thiazide-like diuretics reduce risk of major cardiovascular events and heart failure in hypertensive patients compared with hydrochlorothiazide with a comparable incidence of adverse events. Both thiazide diuretics and thiazide-like diuretics are effective in reducing risk of stroke. Both drug classes appear to have comparable rates of adverse effects as other antihypertensives such as angiotensin II receptor blockers and dihydropyridine calcium channel blockers and lesser prevalence of side-effects when compared to ACE-inhibitors and non-dihydropyridine calcium channel blockers.

<span class="mw-page-title-main">UK Biobank</span> Long-term biobank study of 500,000 people

UK Biobank is a large long-term biobank study in the United Kingdom (UK) which is investigating the respective contributions of genetic predisposition and environmental exposure to the development of disease. It began in 2006. UK Biobank has been cited as an important resource for cancer research.

Sir Richard Peto is an English statistician and epidemiologist who is Professor of Medical Statistics and Epidemiology at the University of Oxford, England.

<span class="mw-page-title-main">Paul Ridker</span> American epidemiologist and academic

Paul M. Ridker is a cardiovascular epidemiologist and biomedical researcher. He is currently the Eugene Braunwald Professor of Medicine at Harvard University and Brigham and Women's Hospital, where he directs the Center for Cardiovascular Disease Prevention. Ridker also holds an appointment as Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health.

<span class="mw-page-title-main">Clinical Trial Service Unit</span>

The Clinical Trial Service Unit (CTSU) is a medical research institute within the Nuffield Department of Population Health at Oxford University. It primarily conducts large scale clinical trials and epidemiological studies of chronic diseases, especially cancer and vascular conditions. It is located in the Richard Doll Building (RDB) on the Old Road Campus, in Headington, Oxford, England.

Dame Valerie Beral AC DBE FRS FRCOG FMedSci was an Australian-born British epidemiologist, academic and a preeminent specialist in breast cancer epidemiology. She was Professor of Epidemiology, a Fellow of Green Templeton College, Oxford and was the Head of the Cancer Epidemiology Unit at the University of Oxford and Cancer Research UK from 1989.

Joanna Marguerite Wardlaw is a Scottish physician, radiologist, and academic specialising in neuroradiology and pathophysiology. Wardlaw worked as a junior doctor before specialising as a radiologist. She continues to practice medicine as an Honorary Consultant Neuroradiologist with NHS Lothian. She has spent her entire academic career at the University of Edinburgh.

The Nuffield Department of Population Health (NDPH) of Oxford University is located at the Old Road Campus in Headington, Oxford, England. It is one of the largest departments within Oxford University's Medical Sciences Division. The head of department is Professor Sir Rory Collins.

Jane Margaret Armitage is a professor of clinical trials and epidemiology in the Clinical Trial Service Unit at the University of Oxford. She works on the epidemiology of cardiovascular disease and has led large-scale randomized controlled trials.

Colin Baigent is a British academic physician and cardiovascular epidemiologist. He is a professor of epidemiology, Director of the Medical Research Council Population Health Research Unit at the University of Oxford, and deputy director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), part of Oxford Population Health. His work is focused in the design and coordination of large-scale randomised trials and the use of meta-analysis to assess the efficacy and safety of drugs for the prevention of cardiovascular disease (CVD) or premature death.

The West of Scotland Coronary Prevention Study was a landmark randomized controlled trial, published in 1995, that investigated the effects of pravastatin, a cholesterol-lowering drug, on primary prevention of coronary heart disease (CHD) in men with hypercholesterolemia. Conducted in the early 1990s, this study provided critical evidence on the benefits of statins in reducing cardiovascular events in individuals without a history of CHD. It concluded that statin treatment reduced CHD events by 31% after nearly five years of treatment.

References

  1. 1 2 3 "COLLINS, Sir Rory (Edwards)" . Who's Who . Vol. 2016 (online Oxford University Press  ed.). Oxford: A & C Black.(Subscription or UK public library membership required.)
  2. 1 2 3 Sudlow, Cathie; Gallacher, John; Allen, Naomi; Beral, Valerie; Burton, Paul; Danesh, John; Downey, Paul; Elliott, Paul; Green, Jane; Landray, Martin; Liu, Bette; Matthews, Paul; Ong, Giok; Pell, Jill; Silman, Alan; Young, Alan; Sprosen, Tim; Peakman, Tim; Collins, Rory (2015). "UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age". PLOS Medicine. 12 (3): e1001779. doi: 10.1371/journal.pmed.1001779 . ISSN   1549-1676. PMC   4380465 . PMID   25826379.
  3. 1 2 3 Allen, N. E.; Sudlow, C.; Peakman, T.; Collins, R. (2014). "UK Biobank Data: Come and Get It". Science Translational Medicine. 6 (224): 224ed4. doi: 10.1126/scitranslmed.3008601 . ISSN   1946-6234. PMID   24553384. S2CID   206684216.
  4. 1 2 3 Collins, Rory (2012). "What makes UK Biobank special?". The Lancet. 379 (9822): 1173–1174. doi:10.1016/S0140-6736(12)60404-8. ISSN   0140-6736. PMID   22463865. S2CID   205965558.
  5. 1 2 3 4 "Sir Rory Collins FMedSci FRS". London: Royal Society. Archived from the original on 17 November 2015. One or more of the preceding sentences incorporates text from the royalsociety.org website where:
    "All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” -- "Royal Society Terms, conditions and policies". Archived from the original on 25 September 2015. Retrieved 9 March 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  6. ↑ Rory Collins's publications indexed by the Scopus bibliographic database. (subscription required)
  7. ↑ Collaboration, A. T. (2002). "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients". BMJ. 324 (7329): 71–86. doi:10.1136/bmj.324.7329.71. ISSN   0959-8138. PMC   64503 . PMID   11786451.
  8. ↑ Heart Protection Study Collaborative Group (2002). "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial". The Lancet. 360 (9326): 7–22. doi:10.1016/S0140-6736(02)09327-3. ISSN   0140-6736. PMID   12114036. S2CID   35836642.
  9. ↑ Rory Collins' profile
  10. ↑ "UK government grants awarded to Rory Collins". Swindon: Research Councils UK. Archived from the original on 18 December 2015.
  11. ↑ "No. 59647". The London Gazette (Supplement). 31 December 2010. p. 1.
  12. ↑ "TIME100 Health". TIME. Retrieved 16 September 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.